Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Myositis

Myositis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Myositis

4 trials tracked for Myositis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 33 citations.

4Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2 Other / NA 1
  1. Phase 3 Belimumab in Idiopathic Inflammatory Myositis Completed · 33 cited
  2. Phase 2 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed
  3. Phase 2 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease Completed
  4. N/A Ultrasound in Muscle Biopsy Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
Drug Pipeline Sys. Review
Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer Toripalimab Treatment Linked to Heart and Muscle Inflammation
This case report and literature review describes a 74-year-old male with stage IIIA lung squamous cell carcinoma who developed multiple immu…
A single case study shows a patient with lung cancer developed heart and muscle inflammation after receiving toripalimab treatment.
Frontiers Oct 24, 2026
Pembrolizumab-induced myositis and cardiogenic shock may be reversible with early immunosuppression and circulatory support
Cardiology Sys. Review
Pembrolizumab-induced myositis and cardiogenic shock may be reversible with early immunosuppression and circulatory support Immune therapy for thymoma can cause severe heart and muscle damage
This case report and literature review describes a patient with stage IV thymoma who developed severe myositis and cardiogenic shock followi…
A new case report reveals how a specific cancer treatment can cause severe heart and muscle issues, requiring intensive life support.
Frontiers Sep 11, 2026
High-dose corticosteroids combined with IVIG or plasma exchange are preferred for triple-M syndrome
Neurology Meta-analysis
High-dose corticosteroids combined with IVIG or plasma exchange are preferred for triple-M syndrome Triple-M Syndrome Linked to Immune Checkpoint Inhibitor Therapy
This systematic review of case reports and series examines the management of triple-M syndrome following immune checkpoint inhibitor therapy…
Patients receiving immune checkpoint inhibitors may develop triple-M syndrome, a serious combination of muscle, heart, and nerve issues requ…
Frontiers Aug 20, 2026